Back to Search
EMMANUEL KATSANIS, MD
MD
Pediatric Hematology & Oncology Physician
NPI: 1720053291Individual
Specialties, Licenses & Credentials
Pediatric Hematology & Oncology PhysicianPrimary
Pediatrics — Pediatric Hematology-Oncology
Code: 2080P0207X
25119(AZ)
Research & Publications (20)
Killer dendritic cells and their potential for cancer immunotherapy.
PMID 19618185·Cancer Immunol Immunother·2010
6-review
A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model.
PMID 18347157·Mol Cancer Ther·2008
7-preclinical
Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression.
PMID 18174364·J Leukoc Biol·2008
7-preclinical
Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
PMID 18608582·Int J Hyperthermia·2008
7-preclinical
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
PMID 18981115·J Immunol·2008
7-preclinical
The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model.
PMID 17466973·Exp Cell Res·2007
7-preclinical
Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro.
PMID 17349014·Clin Exp Immunol·2007
8-other
Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
PMID 17327358·FASEB J·2007
7-preclinical
CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease.
PMID 17234458·Clin Immunol·2007
8-other
Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10.
PMID 16612596·Cancer Immunol Immunother·2007
7-preclinical
Chaperone-rich cell lysates, immune activation and tumor vaccination.
PMID 15887013·Cancer Immunol Immunother·2006
6-review
Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination.
PMID 16989012·Int J Cancer·2006
7-preclinical
Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading.
PMID 16738802·Apoptosis·2006
7-preclinical
Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity.
PMID 16503496·Biol Blood Marrow Transplant·2006
4-observational
Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines.
PMID 16041582·Cancer Immunol Immunother·2006
7-preclinical
Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
PMID 15374884·Blood·2005
7-preclinical
Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway.
PMID 15123887·J Biomed Biotechnol·2004
8-other
Cargo from tumor-expressed albumin inhibits T-cell activation and responses.
PMID 15520220·Cancer Res·2004
7-preclinical
Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia.
PMID 15069690·Int J Cancer·2004
7-preclinical
Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers.
PMID 12669247·Cancer Immunol Immunother·2003
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1501 N CAMPBELL AVE
TUCSON, AZ 85724 - Phone
- (520) 874-3500
Quick Facts
- NPI
- 1720053291
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile